312 related articles for article (PubMed ID: 32804298)
21. K-Ras
Feng H; Zhang Y; Bos PH; Chambers JM; Dupont MM; Stockwell BR
Biochemistry; 2019 May; 58(21):2542-2554. PubMed ID: 31042025
[TBL] [Abstract][Full Text] [Related]
22. Dynamically encoded reactivity of Ras enzymes: opening new frontiers for drug discovery.
Pálfy G; Menyhárd DK; Perczel A
Cancer Metastasis Rev; 2020 Dec; 39(4):1075-1089. PubMed ID: 32815102
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.
Tang D; Kroemer G; Kang R
Mol Cancer; 2021 Oct; 20(1):128. PubMed ID: 34607583
[TBL] [Abstract][Full Text] [Related]
24. KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer.
Casique-Aguirre D; Briseño-Díaz P; García-Gutiérrez P; la Rosa CHG; Quintero-Barceinas RS; Rojo-Domínguez A; Vergara I; Medina LA; Correa-Basurto J; Bello M; Hernández-Rivas R; Del RocioThompson-Bonilla M; Vargas M
BMC Cancer; 2018 Dec; 18(1):1299. PubMed ID: 30594165
[TBL] [Abstract][Full Text] [Related]
25. A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand.
Sun Q; Phan J; Friberg AR; Camper DV; Olejniczak ET; Fesik SW
J Biomol NMR; 2014 Sep; 60(1):11-4. PubMed ID: 25087006
[TBL] [Abstract][Full Text] [Related]
26. Targeting mutated GTPase KRAS in tumor therapies.
Fan G; Lou L; Song Z; Zhang X; Xiong XF
Eur J Med Chem; 2021 Dec; 226():113816. PubMed ID: 34520956
[TBL] [Abstract][Full Text] [Related]
27. Homogeneous Dual-Parametric-Coupled Assay for Simultaneous Nucleotide Exchange and KRAS/RAF-RBD Interaction Monitoring.
Kopra K; Vuorinen E; Abreu-Blanco M; Wang Q; Eskonen V; Gillette W; Pulliainen AT; Holderfield M; Härmä H
Anal Chem; 2020 Apr; 92(7):4971-4979. PubMed ID: 32106676
[TBL] [Abstract][Full Text] [Related]
28. Drugging an undruggable pocket on KRAS.
Kessler D; Gmachl M; Mantoulidis A; Martin LJ; Zoephel A; Mayer M; Gollner A; Covini D; Fischer S; Gerstberger T; Gmaschitz T; Goodwin C; Greb P; Häring D; Hela W; Hoffmann J; Karolyi-Oezguer J; Knesl P; Kornigg S; Koegl M; Kousek R; Lamarre L; Moser F; Munico-Martinez S; Peinsipp C; Phan J; Rinnenthal J; Sai J; Salamon C; Scherbantin Y; Schipany K; Schnitzer R; Schrenk A; Sharps B; Siszler G; Sun Q; Waterson A; Wolkerstorfer B; Zeeb M; Pearson M; Fesik SW; McConnell DB
Proc Natl Acad Sci U S A; 2019 Aug; 116(32):15823-15829. PubMed ID: 31332011
[TBL] [Abstract][Full Text] [Related]
29. Small molecule inhibitors of RAS proteins with oncogenic mutations.
Orgován Z; Keserű GM
Cancer Metastasis Rev; 2020 Dec; 39(4):1107-1126. PubMed ID: 32770300
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of K-RAS4B by a Unique Mechanism of Action: Stabilizing Membrane-Dependent Occlusion of the Effector-Binding Site.
Fang Z; Marshall CB; Nishikawa T; Gossert AD; Jansen JM; Jahnke W; Ikura M
Cell Chem Biol; 2018 Nov; 25(11):1327-1336.e4. PubMed ID: 30122370
[TBL] [Abstract][Full Text] [Related]
31. Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS.
Hodges TR; Abbott JR; Little AJ; Sarkar D; Salovich JM; Howes JE; Akan DT; Sai J; Arnold AL; Browning C; Burns MC; Sobolik T; Sun Q; Beesetty Y; Coker JA; Scharn D; Stadtmueller H; Rossanese OW; Phan J; Waterson AG; McConnell DB; Fesik SW
J Med Chem; 2018 Oct; 61(19):8875-8894. PubMed ID: 30205005
[TBL] [Abstract][Full Text] [Related]
32. The chaperone SmgGDS-607 has a dual role, both activating and inhibiting farnesylation of small GTPases.
García-Torres D; Fierke CA
J Biol Chem; 2019 Aug; 294(31):11793-11804. PubMed ID: 31197034
[TBL] [Abstract][Full Text] [Related]
33. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
Roskoski R
Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
[TBL] [Abstract][Full Text] [Related]
34. 1H, 15N and 13C backbone assignments of GDP-bound human H-Ras mutant G12V.
Amin N; Chiarparin E; Coyle J; Nietlispach D; Williams G
Biomol NMR Assign; 2016 Apr; 10(1):121-3. PubMed ID: 26373425
[TBL] [Abstract][Full Text] [Related]
35. Guanine-nucleotide binding activity, interaction with GTPase-activating protein and solution conformation of the human c-Ha-Ras protein catalytic domain are retained upon deletion of C-terminal 18 amino acid residues.
Fujita-Yoshigaki J; Ito Y; Yamasaki K; Muto Y; Miyazawa T; Nishimura S; Yokoyama S
J Protein Chem; 1992 Dec; 11(6):731-9. PubMed ID: 1466766
[TBL] [Abstract][Full Text] [Related]
36. Second harmonic generation detection of Ras conformational changes and discovery of a small molecule binder.
Donohue E; Khorsand S; Mercado G; Varney KM; Wilder PT; Yu W; MacKerell AD; Alexander P; Van QN; Moree B; Stephen AG; Weber DJ; Salafsky J; McCormick F
Proc Natl Acad Sci U S A; 2019 Aug; 116(35):17290-17297. PubMed ID: 31399543
[TBL] [Abstract][Full Text] [Related]
37. Multi-target, ensemble-based virtual screening yields novel allosteric KRAS inhibitors at high success rate.
Gupta AK; Wang X; Pagba CV; Prakash P; Sarkar-Banerjee S; Putkey J; Gorfe AA
Chem Biol Drug Des; 2019 Aug; 94(2):1441-1456. PubMed ID: 30903639
[TBL] [Abstract][Full Text] [Related]
38. Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function.
Hocker HJ; Cho KJ; Chen CY; Rambahal N; Sagineedu SR; Shaari K; Stanslas J; Hancock JF; Gorfe AA
Proc Natl Acad Sci U S A; 2013 Jun; 110(25):10201-6. PubMed ID: 23737504
[TBL] [Abstract][Full Text] [Related]
39. Quantitative biophysical analysis defines key components modulating recruitment of the GTPase KRAS to the plasma membrane.
Lakshman B; Messing S; Schmid EM; Clogston JD; Gillette WK; Esposito D; Kessing B; Fletcher DA; Nissley DV; McCormick F; Stephen AG; Jean-Francois FL
J Biol Chem; 2019 Feb; 294(6):2193-2207. PubMed ID: 30559287
[TBL] [Abstract][Full Text] [Related]
40. Progress in targeting RAS with small molecule drugs.
McCormick F
Biochem J; 2019 Jan; 476(2):365-374. PubMed ID: 30705085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
